Does Dr. ASHISH BHATIA have financial conflicts of interest?

Dr. ASHISH BHATIA (M.D.) has received a total of $429,769 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $353,480 in personal promotional payouts (consulting, meals, travel) and $76,289 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. ASHISH BHATIA?

According to CMS Open Payments data, Dr. ASHISH BHATIA received funding from ARCUTIS BIOTHERAPEUTICS ($71,021), ENDO PHARMACEUTICALS ($71,014), and MIMEDX GROUP ($54,199).

Does Dr. ASHISH BHATIA receive research grants or speaking fees?

Dr. ASHISH BHATIA has received $353,480 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $76,289 in clinical research grants.

DR. ASHISH BHATIA

M.D.Real-Time Hydrated

Specialty: Dermatology, Procedural Dermatology

Practice Location: ITASCA, IL 60143

NPI Number: 1073595690

LIFETIME INDUSTRY VALUE

$429,769

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. BHATIA is a verified Dermatology, Procedural Dermatology practitioner based in ITASCA, IL.

Between 2021 and 2025, Dr. BHATIA had an overall industry promotional and research financial footprint of $429,769 as recorded in the federal CMS Open Payments database.

$353,480 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$76,289 was allocated to sponsored clinical trials and medical research activities.

Dr. BHATIA's primary funding source is ARCUTIS BIOTHERAPEUTICS, which accounts for $71,021 (representing 16.5% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ARCUTIS BIOTHERAPEUTICS

Rank 1

$71,021

16.5%

ENDO PHARMACEUTICALS

Rank 2

$71,014

16.5%

MIMEDX GROUP

Rank 3

$54,199

12.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.